Efficacy and Prognosis of Apatinib in Treatment of Advanced Gastric Cancer after First-lineChemotherapy
HU Peng,ZHU Xiao-peng
Department of Abdominal Basin and Oncology，Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University，Huangshi 435000,China
Abstract:
Objective To analyze the efficacy and prognosis of apatinib in treatment of advanced gastric cancer after first-line chemotherapy. Methods 92 patients with advanced gastric cancer after first-line chemotherapy in the hospital from January 2016 to December 2017 were selected, and they were divided into groups by randomized controlled method. Control group (46 cases) orally took tegafur; research group (46 cases) orally took apatinib, with 2 courses of treatment in the two groups. The clinical efficacy, adverse reactions,survival rate during 1-year follow-up in the two groups were evaluated. The changes of serum cell factors and survival quality before and after treatment were observed. Results The response rate (RR) and disease control rate (DCR) of research group (56.52%, 80.43%) were higher than those of control group (34.78%, 60.87%),while after 2 courses of treatment, the score of QLQ STO-22 in research group was lower than that in control group (P <0.05); After 2 courses of treatment, the levels of vascular endothelial growth factor (VEGF), soluble interleukin-2 receptor (sIL-2R), interleukin-4 (IL-4), IL-10 in research group were lower than those in control group, while the levels of tumor necrosis factor-α (TNF-α) and γ-interferon (IFN-γ) in research group were higher than those in control group (P <0.05); There was no statistical difference in the incidence of adverse reactions and survival rate between the two groups (P >0.05). Conclusion Apatinib in treatment of advanced gastric cancer after first-line chemotherapy is effective, it can regulate the levels of Th1 and Th2 cell factors,inhibit the release of VEGF level, improve survival quality, decrease the severity of disease, increase the
